

=> s fexofenadine hydrochloride/cn
L1 1 FEXOFENADINE HYDROCHLORIDE/CN

=> fil caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
5.03	5.24

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 09:03:07 ON 12 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Jul 2005 VOL 143 ISS 3
FILE LAST UPDATED: 11 Jul 2005 (20050711/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l1 and amorpho?
129 L1
244729 AMORPHO?
L2 4 L1 AND AMORPHO?

=> d bib abs 1-4

L2 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:77336 CAPLUS
DN 138:126952
TI Polymorphs of fexofenadine hydrochloride
IN Dolitzky, Ben-Zion; Wizel, Shlomit; Krochmal, Barnaba; Diller, Dov; Gross, Irwin
PA Israel
SO U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U. S. Ser. No. 118,807.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003021849	A1	20030130	US 2002-133460	20020426
	US 2002177608	A1	20021128	US 2002-118807	20020408
	CA 2465913	AA	20030515	CA 2002-2465913	20021108
	WO 2003039482	A2	20030515	WO 2002-US35996	20021108
	WO 2003039482	A3	20031120		
	WO 2003039482	C1	20050106		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1453509 A2 20040908 EP 2002-792238 20021108
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

US 2004058955 A1 20040325 US 2003-661259 20030912
 US 2004167168 A1 20040826 US 2004-788924 20040225

PRAI US 2001-282521P P 20010409
 US 2001-307752P P 20010725
 US 2001-314396P P 20010823
 US 2001-336930P P 20011108
 US 2001-339041P P 20011207
 US 2001-344114P P 20011228
 US 2002-361780P P 20020304
 US 2002-363482P P 20020311
 US 2002-118807 A2 20020408
 US 2002-133460 A 20020426
 US 2002-390198P P 20020619
 US 2002-403765P P 20020815
 US 2002-406214P P 20020827
 US 2002-387670P P 20021006
 WO 2002-US35996 W 20021108

AB The present invention provides novel crystal forms of fexofenadine hydrochloride Forms V, VI and VIII-XV and processes for their preparation as well as preparation of **amorphous** form and other crystalline forms of fexofenadine hydrochloride. Forms XIV and XV are solvates of Et acetate, while Form IX is a solvate of MTBE or cyclohexane. The forms are useful for administration to humans and animals to alleviate symptoms caused by histamine. The present invention further provides pharmaceutical compns. of the new crystalline forms.

L2 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:793365 CAPLUS

DN 137:316066

TI Polymorphs of fexofenadine hydrochloride

IN Dolitzky, Ben-Zion; Wizel, Shlomit; Krochmal, Barnaba; Diller, Dov; Gross, Irwin

PA Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.

SO PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN. CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002080857	A2	20021017	WO 2002-US11251	20020408
	WO 2002080857	A3	20031218		
	WO 2002080857	C1	20040527		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
 GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,

GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2444456 AA 20021017 CA 2002-2444456 20020408
 EP 1392303 A2 20040303 EP 2002-733966 20020408

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRAI US 2001-282521P P 20010409
 US 2001-307752P P 20010725
 US 2001-314396P P 20010823
 US 2001-336930P P 20011108
 US 2001-339041P P 20011207
 US 2001-344114P P 20011228
 US 2002-361780P P 20020304
 US 2002-363482P P 20020311
 WO 2002-US11251 W 20020408

AB The present invention provides novel crystal forms of fexofenadine hydrochloride Forms (V, VI and VIII through XV) and processes for their preparation and preparation of **amorphous** form and other crystalline forms of fexofenadine hydrochloride. Forms (XIV and XV) are solvates of Et acetate, while Form IX is anhydrous, but can be crystallized as solvate of

MTBE or cyclohexane. The forms are useful for administration to humans and animals to alleviate symptoms caused by histamine. The present invention further provides pharmaceutical compns. of the new crystalline forms, e.g., capsules and tablets.

L2 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STM
 AN 2002:658079 CAPLUS
 DN 137:201234
 TI Method for producing nonhydrated antiallergic fexofenadine hydrochloride in a novel crystalline form
 IN Kirsch, Volker
 PA Cilag A.-G., Switz.
 SO PCT Int. Appl., 16 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002066429	A1	20020829	WO 2002-CH27	20020117
WO 2002066429	C1	20031106		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2438854	AA	20020829	CA 2002-2438854	20020117
EP 1368313	A1	20031210	EP 2002-742425	20020117
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004520405	T2	20040708	JP 2002-565946	20020117
PRAI CH 2001-329	A	20010223		
WO 2002-CH27	W	20020117		

OS CASREACT 137:201234

AB A nonhydrated fexofenadine hydrochloride is obtained from fexofenadine base and hydrogen chloride either in the form of a novel crystal polymorph, in an **amorphous** form, or in the form of a mixture of different polymorphs. The novel polymorph can be used as a

therapeutically active ingredient and can be processed to form a pharmaceutical containing the same and a pharmaceutically acceptable carrier suitable for use as an antihistaminic agent, an antiallergic agent, and/or a bronchodilating agent.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:841983 CAPLUS
DN 134:21436
TI Preparation of **amorphous** fexofenadine hydrochloride using
solvent method and spray or freezing drying techniques
IN Kumar, Naresh; Khanduri, Chandras Has; Sharma, Mukesh
PA Ranbaxy Laboratories Limited, India
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000071124	A1	20001130	WO 2000-IB708	20000525
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1185266	A1	20020313	EP 2000-927651	20000525
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	IN 1999-DE776	A	19990525		
	WO 2000-IB708	W	20000525		

AB This invention relates to the preparation of **amorphous** form of fexofenadine hydrochloride (I) and to a composition containing it. The process for preparation of **amorphous** form of I comprises (1) dissolving crystalline I in the lower alkanol solvent such as methanol, or in the ketone solvent such as acetone, or in the chlorinated solvent such as chloroform, and (2) recovering **amorphous** I by spray drying or freeze drying technique.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s fexofenadine hydrochloride/cn
L1 1 FEXOFENADINE HYDROCHLORIDE/CN

=>

=> fil caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
5.03	5.24

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 09:11:46 ON 12 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Jul 2005 VOL 143 ISS 3
FILE LAST UPDATED: 11 Jul 2005 (20050711/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l1(l)?furan?
129 L1
195421 ?FURAN?
L2 0 L1(L)?FURAN?

=> s l1 and ?furan?
129 L1
195421 ?FURAN?
L3 3 L1 AND ?FURAN?

=> d bib hit 1-3

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:780365 CAPLUS
DN 141:295728
TI Preparation of benzene derivatives as cannabinoid receptor ligands
IN Shankar, Bandarpalle B.; Rizvi, Razia K.; Kozlowski, Joseph A.; Shih, Neng-Yang
PA Schering Corporation, USA
SO U.S. Pat. Appl. Publ., 53 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004186148	A1	20040923	US 2004-803577	20040318
	WO 2004085385	A2	20041007	WO 2004-US8333	20040318

WO 2004085385 A3 20041125

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-456268P P 20030320

OS MARPAT 141:295728

IT 59-05-2, Methotrexate 378-44-9, β -Methasone 599-79-1, Sulfasalazine 36322-90-4, Feldene 59865-13-3, Cyclosporin 75706-12-6, Leflunomide 79794-75-5, Claritin 83881-52-1, Zyrtec 100643-71-8, Clarinex 145155-23-3, Betaseron 147245-92-9, Copaxone 153439-40-8, Allegra 162011-90-7, Vioxx 169590-42-5, Celebrex 170277-31-3, Remicade 185243-69-0, Enbrel 194739-10-1, Avonex
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of benzene derivs. as cannabinoid receptor ligands with antiinflammatory and immunomodulatory activity)
IT 79-00-5, 1,1,2-Trichloroethane 106-37-6, 1,4-Dibromobenzene 106-93-4, 1,2-Dibromoethane 110-00-9, Furan 110-91-8, Morpholine, reactions 120-72-9, Indole, reactions 122-03-2, 4-Isopropylbenzaldehyde 141-43-5, Ethanolamine, reactions 586-61-8, 4-Isopropylbromobenzene 615-58-7, 2,4-Dibromophenol 659-28-9, 4-Trifluoromethoxybenzaldehyde 2127-03-9 2557-78-0, 2-Fluorothiophenol 2905-21-7, 2-Fluorobenzenesulfonyl chloride 4365-11-1 4946-14-9, 4-Isopropylbenzenethiol 14135-38-7 22037-28-1, 3-Bromofuran 28588-75-2 57260-71-6, N-Boc-piperazine 622407-64-1 762294-76-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzene derivs. as cannabinoid receptor ligands with antiinflammatory and immunomodulatory activity)

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:556104 CAPLUS

DN 137:109489

TI Compositions comprising a polypeptide and an active agent

IN Piccariello, Thomas; Olon, Lawrence P.; Kirk, Randal J.

PA USA

SO U.S. Pat. Appl. Publ., 34 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002099013	A1	20020725	US 2001-933708	20010822
	US 2004087483	A1	20040506	US 2002-136433	20020502
PRAI	US 2000-247556P	P	20001114		
	US 2000-247558P	P	20001114		
	US 2000-247559P	P	20001114		
	US 2000-247560P	P	20001114		
	US 2000-247561P	P	20001114		
	US 2000-247594P	P	20001114		
	US 2000-247595P	P	20001114		
	US 2000-247606P	P	20001114		
	US 2000-247607P	P	20001114		
	US 2000-247608P	P	20001114		
	US 2000-247609P	P	20001114		

US 2000-247610P	P	20001114
US 2000-247611P	P	20001114
US 2000-247612P	P	20001114
US 2000-247620P	P	20001114
US 2000-247621P	P	20001114
US 2000-247634P	P	20001114
US 2000-247635P	P	20001114
US 2000-247698P	P	20001114
US 2000-247699P	P	20001114
US 2000-247700P	P	20001114
US 2000-247701P	P	20001114
US 2000-247702P	P	20001114
US 2000-247797P	P	20001114
US 2000-247798P	P	20001114
US 2000-247799P	P	20001114
US 2000-247800P	P	20001114
US 2000-247801P	P	20001114
US 2000-247802P	P	20001114
US 2000-247803P	P	20001114
US 2000-247804P	P	20001114
US 2000-247805P	P	20001114
US 2000-247807P	P	20001114
US 2000-247832P	P	20001114
US 2000-247833P	P	20001114
US 2000-247926P	P	20001114
US 2000-247927P	P	20001114
US 2000-247928P	P	20001114
US 2000-247929P	P	20001114
US 2000-247930P	P	20001114
US 2000-642820	A2	20000822
US 2000-248607P	P	20001116
US 2001-933708	A2	20010822

IT 50-06-6, Phenobarbital, biological studies 50-18-0, Cyclophosphamide
50-35-1, Thalidomide 50-44-2, Mercaptopurine 50-78-2, Acetylsalicylic
acid 50-81-7, Vitamin C, biological studies 51-21-8, Fluorouracil
51-61-6, Dopamine, biological studies 51-63-8, Dextroamphetamine sulfate
51-98-9, Norethindrone acetate 52-01-7, Spironolactone 52-24-4,
Thiotepa 52-86-8, Haloperidol 53-36-1, Methylprednisolone Acetate
54-31-9, Furosemide 55-63-0, Nitroglycerin 57-63-6, Ethinyl estradiol
58-08-2, Caffeine, biological studies 58-18-4, Methyltestosterone
58-25-3, Chlordiazepoxide 58-33-3, Promethazine hydrochloride 58-55-9,
Theophylline, biological studies 58-61-7, Adenosine, biological studies
58-93-5, Hydrochlorothiazide 59-42-7, Phenylephrine 60-54-8,
Tetracycline 60-87-7, Promethazine 64-31-3, Morphine Sulfate
67-20-9, **Nitrofurantoin** 67-92-5, Dicyclomine hydrochloride
68-19-9, Vitamin B12 68-22-4, Norethindrone 71-58-9,
Medroxyprogesterone acetate 71-68-1, Hydromorphone hydrochloride
74-79-3, Arginine, biological studies 76-41-5, Oxymorphone 76-42-6,
Oxycodone 76-58-4, Ethylmorphine 78-44-4, Carisoprodol 84-02-6,
Prochlorperazine maleate 87-08-1, Penicillin V 87-33-2, Isosorbide
Dinitrate 89-57-6, Mesalamine 90-82-4, Pseudoephedrine 93-14-1,
Guaifenesin 113-45-1, Methylphenidate 113-52-0 113-92-8,
Chlorpheniramine maleate 114-07-8, Erythromycin 124-90-3, Oxycodone
hydrochloride 125-28-0, Dihydrocodeine 125-29-1, Hydrocodone
125-33-7, Primidone 125-71-3, Dextromethorphan 128-13-2, Ursodiol
129-06-6, Warfarin Sodium 132-17-2, Benztropine methanesulfonate
143-52-2, Methyl Dihydromorphine 143-71-5, Hydrocodone bitartrate
152-11-4, Verapamil hydrochloride 297-76-7, Ethynodiol diacetate
298-46-4, Carbamazepine 298-59-9, Methylphenidate hydrochloride
303-49-1, Clomipramine 315-30-0, Allopurinol 318-98-9, Propranolol
Hydrochloride 378-44-9, Betamethasone 379-79-3, Ergotamine Tartrate
437-38-7, Fentanyl 439-14-5, Diazepam 446-86-6, Azathioprine

466-99-9, Hydromorphone 469-62-5, Propoxyphene 509-60-4,
 Dihydromorphone 514-36-3, Fludrocortisone acetate 541-15-1,
 Levocarnitine 549-18-8, Amitriptyline hydrochloride 554-13-2, Lithium
 Carbonate 561-27-3, Diacetylmorphine 595-33-5, Megestrol acetate
 604-75-1, Oxazepam 630-93-3, Sodium phenytoin 657-24-9, Metformin
 745-65-3, Alprostadil 747-36-4, Hydroxychloroquine sulfate 797-63-7,
 Levonorgestrel 846-49-1, Lorazepam 846-50-4, Temazepam 894-71-3,
 Nortriptyline hydrochloride 959-24-0, Sotalol hydrochloride 1134-47-0,
 Baclofen 1403-66-3, Gentamicin 1404-93-9, Vancomycin hydrochloride
 1501-84-4, Rimantadine hydrochloride 1508-65-2, Oxybutynin chloride
 1622-61-3, Clonazepam 1665-48-1, Metaxalone 1744-22-5, Riluzole
 1951-25-3, Amiodarone 2078-54-8, Propofol 2152-34-3, Pemoline
 2375-03-3, Methylprednisolone sodium succinate 4205-91-8 4682-36-4,
 Orphenadrine citrate 4759-48-2, Isotretinoin 5786-21-0, Clozapine
 6202-23-9, Cyclobenzaprine hydrochloride 6493-05-6, Pentoxifylline
 6533-00-2, Norgestrel 7280-37-7, Estropipate 7414-83-7, Etidronate
 disodium 9002-60-2, Adrenocorticotrophic hormone, biological studies
 9002-69-1, Relaxin 9005-49-6, Heparin, biological studies 9014-42-0,
 Thrombopoietin 9039-53-6, Urokinase 9041-08-1, Dalteparin sodium
 9041-92-3, α -1-Protease inhibitor 9080-79-9, Sodium polystyrene
 sulfonate 10238-21-8, Glyburide 11005-12-2, β -Phytosterol
 11056-06-7, Bleomycin 11140-85-5, Glucagon hydrochloride 13311-84-7,
 Flutamide 13614-98-7, Minocycline hydrochloride 14124-50-6,
 Hydrochlorothiazide-triamterene mixture 14611-52-0, Selegiline
 hydrochloride 14838-15-4, Phenylpropanolamine 15307-79-6, Diclofenac
 sodium 15663-27-1, Cisplatin 15686-71-2, Cephalexin 17140-78-2,
 Propoxyphene napsylate 17560-51-9, Metolazone 18559-94-9, Albuterol
 19767-45-4, Mesna 20537-88-6, Amifostine 20830-75-5, Digoxin
 21062-37-3D, analogs 21256-18-8, Oxaprozin 21829-25-4, Nifedipine
 22071-15-4, Ketoprofen 23031-32-5, Terbutaline sulfate 25316-40-9,
 Doxorubicin hydrochloride 25322-68-3, Polyethylene glycol 25332-39-2,
 Trazodone hydrochloride 25614-03-3, Bromocriptine 26159-34-2, Naproxen
 sodium 26787-78-0, Amoxicillin 27164-46-1, Cefazolin sodium
 27314-97-2, Tirapazamine 28860-95-9, Carbidopa 28981-97-7, Alprazolam
 29094-61-9, Glipizide 29354-16-3, Thyronine, iodo- 31677-93-7,
 Bupropion hydrochloride 32222-06-3, Calcitriol 32780-64-6, Labetalol
 hydrochloride 33069-62-4, Paclitaxel 33286-22-5, Diltiazem
 hydrochloride 33419-42-0, Etoposide 33564-30-6, Cefoxitin sodium
 34552-83-5, Loperamide hydrochloride 34580-13-7, Ketotifen 35189-28-7,
 Norgestimate 36282-47-0, Tramadol hydrochloride 36505-84-7, Buspirone
 36791-04-5, Ribavirin 37296-80-3, Colestipol hydrochloride 38398-32-2,
 Ganaxolone 41340-25-4, Etodolac 41575-94-4, Carboplatin 42200-33-9,
 Nadolol 42617-41-4, Activated protein C 42924-53-8, Nabumetone
 49562-28-9, Fenofibrate 49842-07-1, Tobramycin sulfate 50370-12-2,
 Cefadroxil 50700-72-6, Vecuronium bromide 51321-79-0, Sparfosic acid
 51481-61-9, Cimetidine 51773-92-3, Mefloquine hydrochloride
 52232-67-4, Teriparatide 53885-35-1, Ticlopidine hydrochloride
 53994-73-3, Cefaclor 54024-22-5, Desogestrel 54143-56-5, Flecainide
 acetate 54182-58-0, Sucralfate 54910-89-3, Fluoxetine 54965-24-1,
 Tamoxifen citrate 55079-83-9, Acitretin 56180-94-0, Acarbose
 56238-63-2, Cefuroxime sodium 57109-90-7, Clorazepate dipotassium
 57248-88-1, Pamidronate disodium 57852-57-0, Idarubicin hydrochloride
 58579-51-4, Anagrelide hydrochloride 58786-99-5, Butorphanol tartrate
 59122-46-2, Misoprostol 59703-84-3, Piperacillin sodium 59729-32-7,
 Citalopram hydrobromide 59865-13-3, Cyclosporin 59989-18-3, Eniluracil
 60142-96-3, Gabapentin 60205-81-4, Ipratropium 60748-06-3, Gastrin 17
 61718-82-9, Fluvoxamine maleate 62288-83-9, Desmopressin acetate
 62571-86-2, Captopril 63074-08-8, Terazosin hydrochloride 63675-72-9,
 Nisoldipine 64221-86-9, Imipenem 64461-82-1, Tizanidine hydrochloride
 64485-93-4, Cefotaxime sodium 64544-07-6, Cefuroxime axetil
 65277-42-1, Ketoconazole 65646-68-6, Fenretinide 65807-02-5, Goserelin
 66085-59-4, Nimodipine 66104-22-1, Pergolide 66357-35-5, Ranitidine

66722-44-9, Bisoprolol 67889-72-9, Acetaminophen-codeine phosphate mixture
 67992-58-9, Sodium ioxaglate 68562-41-4, Mecasermin 68693-11-8,
 Modafinil 68844-77-9, Astemizole 69655-05-6, Didanosine 70458-96-7,
 Norfloxacin 70476-82-3, Mitoxantrone hydrochloride 72509-76-3,
 Felodipine 72558-82-8, Ceftazidime 72956-09-3, Carvedilol
 73334-07-3, Iopromide 73573-87-2, Formoterol 73590-58-6, Omeprazole
 74103-06-3, Ketorolac 74191-85-8, Doxazosin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compsn. comprising a polypeptide and an active agent)

IT 74356-00-6, Cefotetan disodium 74381-53-6, Leuprolide acetate
 74469-00-4, Amoxicillin-potassium clavulanate mixture 75330-75-5,
 Lovastatin 75695-93-1, Isradipine 75706-12-6, Leflunomide
 75847-73-3, Enalapril 75970-99-9, Norastemizole 76470-66-1, Loracarbef
 76547-98-3, Lisinopril 76584-70-8, Divalproex sodium 76820-74-1,
 Sodium meglumine ioxaglate 76824-35-6, Famotidine 76963-41-2,
 Nizatidine 78246-49-8, Paroxetine hydrochloride 78628-80-5,
 Terbinafine hydrochloride 78755-81-4, Flumazenil 79307-93-0,
 Azelastine hydrochloride 79350-37-1, Cefixime 79517-01-4, Octreotide
 acetate 79794-75-5, Loratadine 79902-63-9, Simvastatin 81098-60-4,
 Cisapride 81103-11-9, Clarithromycin 81129-83-1, Cilastatin sodium
 81131-70-6, Pravastatin sodium 81409-90-7, Cabergoline 81627-83-0,
 M-CSF 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin 82586-52-5,
 Moexipril hydrochloride 82586-55-8, Quinapril hydrochloride
 82626-48-0, Zolpidem 82640-04-8, Raloxifene hydrochloride 82657-92-9,
 Prourokinase 82752-99-6, Nefazodone hydrochloride 83015-26-3,
 Tomoxetine 83881-52-1, Cetirizine hydrochloride 83905-01-5,
 Azithromycin 83928-66-9, Gepirone hydrochloride 84057-84-1,
 Lamotrigine 84485-00-7, Sibutramine hydrochloride 84625-61-6,
 Itraconazole 85650-52-8, Mirtazapine 85721-33-1, Ciprofloxacin
 86050-77-3, Gadopentetate dimeglumine 86386-73-4, Fluconazole
 86541-74-4, Benazepril hydrochloride 87239-81-4, Cefpodoxime proxetil
 87333-19-5, Ramipril 87679-37-6, Trandolapril 90357-06-5, Bicalutamide
 90566-53-3, Fluticasone 91374-20-8, Ropinirole hydrochloride
 91421-42-0, Rubitecan 91832-40-5, Cefdinir 92134-98-0, Fosphenytoin
 sodium 92339-11-2, Iodixanol 92665-29-7, Cefprozil 93379-54-5,
 Esatenolol 93479-97-1, Glimepiride 93957-54-1, Fluvastatin
 95233-18-4, Atovaquone 95635-56-6, Ranolazine hydrochloride
 95896-08-5, Anaritide 96036-03-2, Meropenem 96829-58-2, Orlistat
 96946-42-8, Cisatracurium besylate 97240-79-4, Topiramate 97322-87-7,
 Troglitazone 97519-39-6, Ceftibuten 98048-97-6, Fosinopril
 98319-26-7, Finasteride 98418-47-4, Metoprolol succinate 99300-78-4,
 Venlafaxine hydrochloride 99614-01-4, Ondansetron hydrochloride
 100286-90-6, Irinotecan hydrochloride 100286-97-3, Milrinone lactate
 100986-85-4, Levofloxacin 103475-41-8, Tepoxalin 103577-45-3,
 Lansoprazole 104227-87-4, Fanciclovir 104632-25-9, Pramipexole
 dihydrochloride 106266-06-2, Risperidone 106392-12-5, Poloxamer 188
 106861-44-3, Mivacurium chloride 107007-99-8, Granisetron hydrochloride
 107753-78-6, Zafirlukast 111470-99-6, Amlodipine besylate 111974-72-2,
 Quetiapine fumarate 112108-01-7, Ecopipam 112529-15-4, Pioglitazone
 hydrochloride 112573-73-6, Ecadotril 112733-06-9, Zenarestat
 113427-24-0, Epoetin alfa 114977-28-5, Docetaxel 115956-13-3,
 Dolasetron mesylate 116539-59-4, Duloxetine 117976-90-6, Rabeprazole
 sodium 118390-30-0, Interferon alfacon-1 119302-91-9, Rocuronium
 bromide 119413-54-6, Topotecan hydrochloride 120011-70-3, Donepezil
 hydrochloride 120066-54-8, Gadoteridol 120202-66-6, Clopidogrel
 bisulfate 120511-73-1, Anastrozole 120635-74-7, Cilansetron
 121032-29-9, Nelarabine 121181-53-1D, PEGylated 121584-18-7, Valspodar
 122111-03-9, Gemcitabine hydrochloride 123122-55-4, Candoxatril
 123258-84-4, Itasetron 124584-08-3, Nesiritide 124750-99-8, Losartan
 potassium 124832-27-5, Valacyclovir hydrochloride 124937-52-6,
 Tolterodine tartrate 125317-39-7, Vinorelbine tartrate 126544-47-6,
 Ciclesonide 127254-12-0, Sitafloxacin 127779-20-8, Saquinavir

128298-28-2, Remacemide 128794-94-5, Mycophenolate mofetil
 129318-43-0, Alendronate sodium 129580-63-8, Satraplatin 129618-40-2,
 Nevirapine 129722-12-9, Aripiprazole 130018-77-8, Levocetirizine
 130325-35-8, PD 135158 131918-61-1, Paricalcitol 132449-46-8,
 Lesopitron 132539-06-1, Olanzapine 133107-64-9, Insulin lispro
 133737-32-3, Pagoclone 134523-03-8, Atorvastatin calcium 134564-82-2,
 Befloxatone 134678-17-4, Lamivudine 135062-02-1, Repaglinide
 135306-42-2, BW 1555U88 135354-02-8, Xaliproden 137234-62-9,
 Voriconazole 137281-23-3, Pemetrexed 137862-53-4, Valsartan
 138402-11-6, Irbesartan 138531-07-4, Sinapultide 138660-96-5,
 Sevirumab 139264-17-8, Zolmitriptan 140207-93-8, Pentosan polysulfate
 sodium 141579-67-1, A 78773 141732-76-5, Exendin-4 142340-99-6,
 Adefovir dipivoxil 142373-60-2, Tirofiban hydrochloride 142880-36-2,
 Ilomastat 143201-11-0, Cerivastatin sodium 143388-64-1, Naratriptan
 hydrochloride 144980-29-0, Repinotan 145040-37-5, Candesartan
 cilexetil 145202-66-0, Rizatriptan benzoate 145258-61-3, Interferon
 β1 (human fibroblast protein moiety) 145375-43-5, Mitiglinide
 145821-59-6, Tiagabine hydrochloride 145941-26-0, Oprelvekin
 146479-72-3 147059-75-4, Trovafloxacin mesylate 147245-92-9,
 Glatiramer acetate 147536-97-8, Bosentan 148553-50-8, Pregabalin
 148883-56-1, Tifacogin 149824-15-7, Ilodecakin 149845-06-7, Saquinavir
 mesylate 149950-60-7, Emivirine 151035-56-2 151063-30-8,
 Lisinopril-hydrochlorothiazide mixture 151319-34-5, Zaleplon
 151767-02-1, Montelukast sodium 152751-57-0, Sevelamer hydrochloride
 153168-05-9, Pleconaril 153259-65-5, Cilomilast 153438-49-4, Dapitant
153439-40-8, Fexofenadine hydrochloride 153773-82-1, MK 826
 154039-60-8, Marimastat 154248-97-2, Imiglucerase 154361-50-9,
 Capecitabine 154598-52-4, Efavirenz 155141-29-0, Rosiglitazone maleate
 155213-67-5, Ritonavir 156154-37-9, Losartan-hydrochlorothiazide mixture
 157263-00-8, L 159282 157542-49-9, CS 834 157810-81-6, Indinavir
 sulfate 159989-65-8, Nelfinavir mesylate 160135-92-2 161814-49-9,
 Amprenavir 162011-90-7, Rofecoxib 162808-62-0, Caspofungin
 164656-23-9, Dutasteride 166089-32-3, Lintuzumab 166374-48-7, CVT 124
 166518-60-1, Avasimibe 169148-63-4, NN 304 169590-42-5, Celecoxib
 170277-31-3, Infliximab 171228-49-2, Posaconazole 171599-83-0,
 Sildenafil citrate 178961-24-5, 264W94 179120-92-4, Altinicine
 180288-69-1, Trastuzumab 181069-80-7, ALT 711 181695-72-7, Valdecocix
 182167-03-9, EM 800 183547-57-1, Gantofiban 183552-38-7, Abarelix
 185243-69-0, Etanercept 187348-17-0, Edodekin alfa 187523-35-9, BMS
 204352 188039-54-5, Palivizumab 188062-50-2, Abacavir sulfate
 188627-80-7, Eptifibatide 189013-61-4, 4030W92 192329-42-3,
 Prinomastat 193079-69-5, Tabimorelin 198153-51-4, Peginterferon
 alfa-2a 198283-73-7, ABT 594 202138-50-9, Tenofovir disoproxil
 fumarate 202409-33-4, Etoricoxib 205110-48-1, ABT 773 208538-73-2,
 FK 463 210101-16-9, Conivaptan 223652-82-2, BMS 284756 332348-12-6,
 BMS 188667

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (comps. comprising a polypeptide and an active agent)

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:332011 CAPLUS
 DN 136:355482
 TI Compositions comprising a polypeptide and an active agent
 IN Piccariello, Thomas; Olon, Lawrence P.; Kirk, Randall J.
 PA New River Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 98 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 12

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI	WO 2002034237	A1	20020502	WO 2001-US26142	20010822
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 6716452	B1	20040406	US 2000-642820	20000822
	CA 2420590	AA	20020502	CA 2001-2420590	20010822
	AU 2001086599	A5	20020506	AU 2001-86599	20010822
	EP 1311242	A1	20030521	EP 2001-966056	20010822
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004523480	T2	20040805	JP 2002-537291	20010822
	US 2004127397	A1	20040701	US 2003-727565	20031205
PRAI	US 2000-642820	A	20000822		
	US 2000-247613P	P	20001114		
	US 2000-247614P	P	20001114		
	US 2000-247615P	P	20001114		
	US 2000-247616P	P	20001114		
	US 2000-247617P	P	20001114		
	US 2000-247622P	P	20001114		
	US 2000-247630P	P	20001114		
	US 2000-247631P	P	20001114		
	US 2000-247632P	P	20001114		
	US 2000-247633P	P	20001114		
	US 2000-247556P	P	20001114		
	US 2000-247558P	P	20001114		
	US 2000-247559P	P	20001114		
	US 2000-247560P	P	20001114		
	US 2000-247561P	P	20001114		
	US 2000-247594P	P	20001114		
	US 2000-247595P	P	20001114		
	US 2000-247606P	P	20001114		
	US 2000-247607P	P	20001114		
	US 2000-247608P	P	20001114		
	US 2000-247609P	P	20001114		
	US 2000-247610P	P	20001114		
	US 2000-247611P	P	20001114		
	US 2000-247612P	P	20001114		
	US 2000-247620P	P	20001114		
	US 2000-247621P	P	20001114		
	US 2000-247634P	P	20001114		
	US 2000-247635P	P	20001114		
	US 2000-247698P	P	20001114		
	US 2000-247699P	P	20001114		
	US 2000-247701P	P	20001114		
	US 2000-247702P	P	20001114		
	US 2000-247797P	P	20001114		
	US 2000-247798P	P	20001114		
	US 2000-247799P	P	20001114		
	US 2000-247800P	P	20001114		
	US 2000-247801P	P	20001114		
	US 2000-247802P	P	20001114		
	US 2000-247803P	P	20001114		
	US 2000-247804P	P	20001114		
	WO 2001-US26142	W	20010822		

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 50-06-6, Phenobarbital, biological studies 50-18-0, Cyclophosphamide
50-35-1, Thalidomide 50-44-2, Mercaptopurine 50-78-2, Acetylsalicylic
acid 50-81-7, Vitamin C, biological studies 51-21-8, Fluorouracil
51-61-6, Dopamine, biological studies 51-63-8, Dextroamphetamine sulfate
51-98-9, Norethindrone acetate 52-01-7, Spironolactone 52-24-4,
Thiotepa 52-86-8, Haloperidol 53-36-1, Methylprednisolone Acetate
54-31-9, Furosemide 55-63-0, Nitroglycerin 57-63-6, Ethinyl estradiol
58-08-2, Caffeine, biological studies 58-18-4, Methyltestosterone
58-25-3, Chlordiazepoxide 58-33-3, Promethazine hydrochloride 58-55-9,
Theophylline, biological studies 58-61-7, Adenosine, biological studies
58-93-5, Hydrochlorothiazide 59-42-7, Phenylephrine 60-54-8,
Tetracycline 60-87-7, Promethazine 64-31-3, Morphine Sulfate
67-20-9, Nitrofurantoin 67-92-5, Dicyclomine hydrochloride
68-19-9, Vitamin B12 68-22-4, Norethindrone 71-58-9,
Medroxyprogesterone acetate 71-68-1, Hydromorphone hydrochloride
74-79-3, Arginine, biological studies 76-41-5, Oxymorphone 76-42-6,
Oxycodone 76-58-4, Ethylmorphine 78-44-4, Carisoprodol 84-02-6;
Prochlorperazine maleate 87-08-1, Penicillin V 87-33-2, Isosorbide
Dinitrate 89-57-6, Mesalamine 90-82-4, Pseudoephedrine 93-14-1,
Guaifenesin 113-45-1, Methylphenidate 113-52-0 113-92-8,
Chlorpheniramine maleate 114-07-8, Erythromycin 124-90-3, Oxycodone
hydrochloride 125-28-0, Dihydrocodeine 125-29-1, Hydrocodone
125-33-7, Primidone 125-71-3, Dextromethorphan 128-13-2, Ursodiol
129-06-6, Warfarin Sodium 132-17-2, Benzatropine methanesulfonate
132-22-9, Chlorpheniramine 143-52-2, Methylidihydromorphinone 143-71-5,
Hydrocodone bitartrate 152-11-4, Verapamil hydrochloride 297-76-7,
Ethynodiol diacetate 298-46-4, Carbamazepine 298-59-9, Methylphenidate
hydrochloride 303-49-1, Clomipramine 315-30-0, Allopurinol 318-98-9,
Propranolol Hydrochloride 378-44-9, Betamethasone 379-79-3, Ergotamine
Tartrate 437-38-7, Fentanyl 439-14-5, Diazepam 446-86-6,
Azathioprine 466-99-9, Hydromorphone 469-62-5, Propoxyphene
509-60-4, Dihydromorphone 514-36-3, Fludrocortisone acetate 541-15-1,
Levocarnitine 549-18-8, Amitriptyline hydrochloride 554-13-2, Lithium
Carbonate 561-27-3, Diacetylmorphine 595-33-5, Megestrol acetate
604-75-1, Oxazepam 630-93-3, Sodium phenytoin 657-24-9, Metformin
745-65-3, Alprostadil 747-36-4, Hydroxychloroquine sulfate 797-63-7,
Levonorgestrel 846-49-1, Lorazepam 846-50-4, Temazepam 894-71-3,
Nortriptyline hydrochloride 959-24-0, Sotalol hydrochloride 1134-47-0,
Baclofen 1403-66-3, Gentamicin 1404-93-9, Vancomycin hydrochloride
1501-84-4, Rimantadine hydrochloride 1508-65-2, Oxybutynin chloride
1622-61-3, Clonazepam 1665-48-1, Metaxalone 1744-22-5, Riluzole
1951-25-3, Amiodarone 2078-54-8, Propofol 2152-34-3, Pemoline
2375-03-3, Methylprednisolone sodium succinate 4205-91-8 4682-36-4,
Orphenadrine citrate 4759-48-2, Isotretinoin 5786-21-0, Clozapine
6202-23-9, Cyclobenzaprine hydrochloride 6493-05-6, Pentoxifylline
6533-00-2, Norgestrel 7280-37-7, Estropipate 7414-83-7, Etidronate
disodium 9002-60-2, Adrenocorticotrophic hormone, biological studies
9002-69-1, Relaxin 9005-49-6, Heparin, biological studies 9014-42-0,
Thrombopoietin 9039-53-6, Urokinase 9041-08-1, Dalteparin sodium
9041-92-3, . α .1-Protease inhibitor 9080-79-9, Sodium polystyrene
sulfonate 10238-21-8, Glyburide 11005-12-2, β -Phytosterol
11056-06-7, Bleomycin 11140-85-5, Glucagon hydrochloride 13311-84-7,
Flutamide 13614-98-7, Minocycline hydrochloride 14124-50-6,
Hydrochlorothiazide-triamterene mixture 14611-52-0, Selegiline
hydrochloride 14838-15-4, Phenylpropanolamine 15307-79-6, Diclofenac
sodium 15663-27-1, Cisplatin 15686-71-2, Cephalexin 17140-78-2,
Propoxyphene napsylate 17560-51-9, Metolazone 18559-94-9, Albuterol
19767-45-4, Mesna 20537-88-6, Amifostine 20830-75-5, Digoxin
21062-37-3D, analogs 21256-18-8, Oxaprozin 21829-25-4, Nifedipine
22071-15-4, Ketoprofen 23031-32-5, Terbutaline sulfate 25316-40-9,
Doxorubicin hydrochloride 25322-68-3, Polyethylene glycol 25332-39-2,
Trazodone hydrochloride 25614-03-3, Bromocriptine 26159-34-2, Naproxen

sodium 26787-78-0, Amoxicillin 27164-46-1, Cefazolin sodium 27314-97-2, Tirapazamine 28860-95-9, Carbidopa 28981-97-7, Alprazolam 29094-61-9, Glipizide 29354-16-3, Thyronine, iodo- 31677-93-7, Bupropion hydrochloride 32222-06-3, Calcitriol 32780-64-6, Labetalol hydrochloride 33069-62-4, Paclitaxel 33286-22-5, Diltiazem hydrochloride 33419-42-0, Etoposide 33564-30-6, Cefoxitin sodium 34552-83-5, Loperamide hydrochloride 34580-13-7, Ketotifen 35189-28-7, Norgestimate 36282-47-0, Tramadol hydrochloride 36505-84-7, Buspirone 36791-04-5, Ribavirin 37296-80-3, Colestipol hydrochloride 38398-32-2, Ganaxolone 41340-25-4, Etodolac 41575-94-4, Carboplatin 42200-33-9, Nadolol 42617-41-4, Activated protein C 42924-53-8, Nabumetone 49562-28-9, Fenofibrate 49842-07-1, Tobramycin sulfate 50370-12-2, Cefadroxil 50700-72-6, Vecuronium bromide 51321-79-0, Sparfloxacin 51481-61-9, Cimetidine 51773-92-3, Mefloquine hydrochloride 52232-67-4, Teriparatide 53885-35-1, Ticlopidine hydrochloride 53994-73-3, Cefaclor 54024-22-5, Desogestrel 54143-56-5, Flecainide acetate 54182-58-0, Sucralfate 54910-89-3, Fluoxetine 54965-24-1, Tamoxifen citrate 55079-83-9, Acitretin 56180-94-0, Acarbose 56238-63-2, Cefuroxime sodium 57109-90-7, Clorazepate dipotassium 57248-88-1, Pamidronate disodium 57852-57-0, Idarubicin hydrochloride 58579-51-4, Anagrelide hydrochloride 58786-99-5, Butorphanol tartrate 59122-46-2, Misoprostol 59703-84-3, Piperacillin sodium 59729-32-7, Citalopram hydrobromide 59865-13-3, Cyclosporin 59989-18-3, Eniluracil 60142-96-3, Gabapentin 60205-81-4, Ipratropium 60748-06-3, Gastrin 17 61718-82-9, Fluvoxamine maleate 62288-83-9, Desmopressin acetate 62571-86-2, Captopril 63074-08-8, Terazosin hydrochloride 63675-72-9, Nisoldipine 64221-86-9, Imipenem 64461-82-1, Tizanidine hydrochloride 64485-93-4, Cefotaxime sodium 64544-07-6, Cefuroxime axetil 65277-42-1, Ketoconazole 65646-68-6, Fenretinide 65807-02-5, Goserelin 66085-59-4, Nimodipine 66104-22-1, Pergolide 66357-35-5, Ranitidine 66722-44-9, Bisoprolol 67889-72-9, Acetaminophen-codeine phosphate mixture 67992-58-9, Sodium ioxaglate 68562-41-4, Mecasermin 68693-11-8, Modafinil 68844-77-9, Astemizole 69655-05-6, Didanosine 70458-96-7, Norfloxacin 70476-82-3, Mitoxantrone hydrochloride 72509-76-3, Felodipine 72558-82-8, Ceftazidime 72956-09-3, Carvedilol 73334-07-3, Iopromide 73573-87-2, Formoterol 73590-58-6, Omeprazole 74103-06-3, Ketorolac

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(comps. comprising a polypeptide and an active agent)

IT 74191-85-8, Doxazosin 74356-00-6, Cefotetan disodium 74381-53-6, Leuprolide acetate 74469-00-4, Amoxicillin-potassium clavulanate mixture 75330-75-5, Lovastatin 75695-93-1, Isradipine 75706-12-6, Leflunomide 75847-73-3, Enalapril 75970-99-9, Norastemizole 76470-66-1, Loracarbef 76547-98-3, Lisinopril 76584-70-8, Divalproex sodium 76820-74-1, Sodium meglumine ioxaglate 76824-35-6, Famotidine 76963-41-2, Nizatidine 78246-49-8, Paroxetine hydrochloride 78628-80-5, Terbinafine hydrochloride 78755-81-4, Flumazenil 79307-93-0, Azelastine hydrochloride 79350-37-1, Cefixime 79517-01-4, Octreotide acetate 79794-75-5, Loratadine 79902-63-9, Simvastatin 81098-60-4, Cisapride 81103-11-9, Clarithromycin 81129-83-1, Cilastatin sodium 81131-70-6, Pravastatin sodium 81409-90-7, Cabergoline 81627-83-0, M-CSF 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin 82586-52-5, Moexipril hydrochloride 82586-55-8, Quinapril hydrochloride 82626-48-0, Zolpidem 82640-04-8, Raloxifene hydrochloride 82657-92-9, Prourokinase 82752-99-6, Nefazodone hydrochloride 83015-26-3, Tomoxetine 83881-52-1, Cetirizine hydrochloride 83905-01-5, Azithromycin 83928-66-9, Gepirone hydrochloride 84057-84-1, Lamotrigine 84485-00-7, Sibutramine hydrochloride 84625-61-6, Itraconazole 85650-52-8, Mirtazapine 85721-33-1, Ciprofloxacin 86050-77-3, Gadopentetate dimeglumine 86386-73-4, Fluconazole 86541-74-4, Benazepril hydrochloride 87239-81-4, Cefpodoxime proxetil 87333-19-5, Ramipril 87679-37-6, Trandolapril 90357-06-5, Bicalutamide

90566-53-3, Fluticasone 91374-20-8, Ropinirole hydrochloride
 91421-42-0, Rubitecan 91832-40-5, Cefdinir 92134-98-0, Fosphenytoin
 sodium 92339-11-2, Iodixanol 92665-29-7, Cefprozil 93379-54-5,
 Esatenolol 93479-97-1, Glimepiride 93957-54-1, Fluvastatin
 95233-18-4, Atovaquone 95635-56-6, Ranolazine hydrochloride
 95896-08-5, Anaritide 96036-03-2, Meropenem 96829-58-2, Orlistat
 96946-42-8, Cisatracurium besylate 97240-79-4, Topiramate 97322-87-7,
 Troglitazone 97519-39-6, Ceftibuten 98048-97-6, Fosinopril
 98319-26-7, Finasteride 98418-47-4, Metoprolol succinate 99300-78-4,
 Venlafaxine hydrochloride 99614-01-4, Ondansetron hydrochloride
 100286-90-6, Irinotecan hydrochloride 100286-97-3, Milrinone lactate
 100986-85-4, Levofloxacin 103475-41-8, Tepoxalin 103577-45-3,
 Lansoprazole 104227-87-4, Famciclovir 104632-25-9, Pramipexole
 dihydrochloride 106266-06-2, Risperidone 106392-12-5, Poloxamer 188
 106861-44-3, Mivacurium chloride 107007-99-8, Granisetron hydrochloride
 107753-78-6, Zafirlukast 111470-99-6, Amlodipine besylate 111974-72-2,
 Quetiapine fumarate 112108-01-7, Ecopipam 112529-15-4, Pioglitazone
 hydrochloride 112573-73-6, Ecadotril 112733-06-9, Zenarestat
 113427-24-0, Epoetin alfa 114977-28-5, Docetaxel 115956-13-3,
 Dolasetron mesylate 116539-59-4, Duloxetine 117976-90-6, Rabeprazole
 sodium 118390-30-0, Interferon alfacon-1 119302-91-9, Rocuronium
 bromide 119413-54-6, Topotecan hydrochloride 120011-70-3, Donepezil
 hydrochloride 120066-54-8, Gadoteridol 120202-66-6, Clopidogrel
 bisulfate 120511-73-1, Anastrozole 120635-74-7, Cilansetron
 121032-29-9, Nelarabine 121181-53-1D, PEGylated 121584-18-7, Valspodar
 122111-03-9, Gemcitabine hydrochloride 123122-55-4, Candoxatril
 123258-84-4, Itasetron 124584-08-3, Nesiritide 124750-99-8, Losartan
 potassium 124832-27-5, Valacyclovir hydrochloride 124937-52-6,
 Tolterodine tartrate 125317-39-7, Vinorelbine tartrate 126544-47-6,
 Ciclesonide 127254-12-0, Sitafloracin 127779-20-8, Saquinavir
 128298-28-2, Remacemide 128794-94-5, Mycophenolate mofetil
 129318-43-0, Alendronate sodium 129580-63-8, Satraplatin 129618-40-2,
 Nevirapine 129722-12-9, Aripiprazole 130018-77-8, Levocetirizine
 130325-35-8, PD 135158 131918-61-1, Paricalcitol 132449-46-8,
 Lesopitron 132539-06-1, Olanzapine 133107-64-9, Insulin lispro
 133737-32-3, Pagoclone 134523-03-8, Atorvastatin calcium 134564-82-2,
 Befloxatone 134678-17-4, Lamivudine 135062-02-1, Repaglinide
 135306-42-2, BW 1555U88 135354-02-8, Xaliproden 137234-62-9,
 Voriconazole 137281-23-3, Pemetrexed 137862-53-4, Valsartan
 138402-11-6, Irbesartan 138531-07-4, Sinapultide 138660-96-5,
 Sevirumab 139264-17-8, Zolmitriptan 140207-93-8, Pentosan polysulfate
 sodium 141579-67-1, A 78773 141732-76-5, Exendin-4 142340-99-6,
 Adefovir dipivoxil 142373-60-2, Tirofiban hydrochloride 142880-36-2,
 Ilomastat 143201-11-0, Cerivastatin sodium 143388-64-1, Naratriptan
 hydrochloride 144980-29-0, Repinotan 145040-37-5, Candesartan
 cilexetil 145202-66-0, Rizatriptan benzoate 145258-61-3, Interferon
 β1 (human fibroblast protein moiety) 145375-43-5, Mitiglinide
 145821-59-6, Tiagabine hydrochloride 145941-26-0, Oprelvekin
 146479-72-3 147059-75-4, Trovafloxacin mesylate 147245-92-9,
 Glatiramer acetate 147536-97-8, Bosentan 148553-50-8, Pregabalin
 148883-56-1, Tifacogin 149824-15-7, Ilodecakin 149845-06-7, Saquinavir
 mesylate 149950-60-7, Emivirine 151035-56-2 151063-30-8,
 Lisinopril-hydrochlorothiazide mixture 151319-34-5, Zaleplon
 151767-02-1, Montelukast sodium 152751-57-0, Sevelamer hydrochloride
 153168-05-9, Pleconaril 153259-65-5, Cilomilast 153438-49-4, Dapitant
153439-40-8, Fexofenadine hydrochloride 153773-82-1, MK 826
 154039-60-8, Marimastat 154248-97-2, Imiglucerase 154361-50-9,
 Capecitabine 154598-52-4, Efavirenz 155141-29-0, Rosiglitazone maleate
 155213-67-5, Ritonavir 156154-37-9, Losartan-hydrochlorothiazide mixture
 157263-00-8, L 159282 157542-49-9, CS 834 157810-81-6, Indinavir
 sulfate 159989-65-8, Nelfinavir mesylate 160135-92-2 161814-49-9,
 Amprenavir 162011-90-7, Rofecoxib 162808-62-0, Caspofungin

164656-23-9, Dutasteride 166089-32-3, Lintuzumab 166374-48-7, CVT 124
 166518-60-1, Avasimibe 169148-63-4, NN 304 169590-42-5, Celecoxib
 170277-31-3, Infliximab 171228-49-2, Posaconazole 171599-83-0,
 Sildenafil citrate 178961-24-5, 264W94 179120-92-4, Altinicine
 180288-69-1, Trastuzumab 181069-80-7, ALT 711 181695-72-7, Valdecoxib
 182167-03-9, EM 800 183547-57-1, Gantofiban 183552-38-7, Abarelix
 185243-69-0, Etanercept 187348-17-0, Edodekin alfa 187523-35-9, BMS
 204352 188039-54-5, Palivizumab 188062-50-2, Abacavir sulfate
 188627-80-7, Eptifibatide 189013-61-4, 4030W92 192329-42-3,
 Prinomastat 193079-69-5, Tabimorelin 198153-51-4, Peginterferon
 alfa-2a 198283-73-7, ABT 594 202138-50-9, Tenofovir disoproxil
 fumarate 202409-33-4, Etoricoxib 205110-48-1, ABT 773 208538-73-2,
 FK 463 210101-16-9, Conivaptan 223652-82-2, BMS 284756 332348-12-6,
 BMS 188667

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (comps. comprising a polypeptide and an active agent)

=> s fexofenadine(1)?furan?

485 FEXOFENADINE

195421 ?FURAN?

L4 5 FEXOFENADINE(L)?FURAN?

=> s l4 not l3

L5 5 L4 NOT L3

=> d bib hit 1-5

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:990445 CAPLUS

DN 140:331546

TI The effects of fruit juices on drug disposition: a new model for drug interactions

AU Dresser, G. K.; Bailey, D. G.

CS Department of Medicine, London Health Sciences Centre, London, ON, Can.

SO European Journal of Clinical Investigation (2003), 33(Suppl. 2), 10-16

CODEN: EJCIB8; ISSN: 0014-2972

PB Blackwell Publishing Ltd.

DT Journal; General Review

LA English

RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB A review. Grapefruit juice produces mechanism-based inhibition of intestinal drug metabolism when consumed in normal quantities. This can produce clin. important increases in oral drug bioavailability when coadministered with substrates of cytochrome P 450 3A4 (CYP3A4) that undergo high presystemic metabolism **Furanocoumarins** such as bergamottin and 6',7'-dihydroxybergamottin have been identified as probable active constituents. Grapefruit juice may also inhibit intestinal P-glycoprotein-mediated efflux transport of drugs such as cyclosporine to increase its oral bioavailability. However, grapefruit juice does not enhance the absorption of digoxin, a prototypical P-glycoprotein substrate, likely because it has high inherent oral bioavailability. Grapefruit and other fruit juices have recently been shown to be potent in vitro inhibitors of a number of organic anion-transporting polypeptides (OATPs). These juices were also found to decrease the absorption of the non-metabolized OATP substrate, **fexofenadine**. Taken together, the data support inhibition of intestinal uptake transporters by fruit juices to decrease drug bioavailability. This would represent a new mechanism for food-drug interactions. These findings with grapefruit and other fruit juices continue to enhance the understanding of

the complex nature of food-drug interactions, and their possible influence on the clin. effects of medications.

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:743368 CAPLUS
 DN 140:19940
 TI Determination of residual solvents in fexofenadine by capillary gas chromatography
 AU Zhang, Ting; He, Lingyun
 CS Department of Pharmacy, Xiangya Hospital, Zhongnan University, Changsha, 410008, Peop. Rep. China
 SO Guangdong Yaoxueyuan Xuebao (2002), 18(4), 284-285
 CODEN: GYXUF8; ISSN: 1006-8783
 PB Guangdong Yaoxueyuan
 DT Journal
 LA Chinese
 IT 60-29-7, Ethyl ether, analysis 64-17-5, Ethanol, analysis 67-56-1, Methanol, analysis 67-64-1, Acetone, analysis 68-12-2, DMF, analysis 75-09-2, Dichloromethane, analysis 109-99-9, Tetrahydrofuran, analysis 141-78-6, Ethyl acetate, analysis
 RL: ANT (Analyte); ANST (Analytical study)
 (determination of residual solvents in **fexofenadine** by capillary gas chromatog.)

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2002:977790 CAPLUS
 DN 138:55873
 TI Preparation of fexofenadine and related compounds.
 IN Schroeder, Collin; Huddleston, Ryan; Charles, Richard
 PA Aventis Pharma Deutschland GmbH, Germany
 SO PCT Int. Appl., 55 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002102776	A1	20021227	WO 2002-EP6424	20020612
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003105329	A1	20030605	US 2002-166893	20020611
	US 6743941	B2	20040601		
	CA 2450313	AA	20021227	CA 2002-2450313	20020612
	EP 1401816	A1	20040331	EP 2002-754657	20020612
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002010410	A	20040817	BR 2002-10410	20020612
	JP 2005502603	T2	20050127	JP 2003-505319	20020612
	ZA 2003008697	A	20040903	ZA 2003-8697	20031107
	US 2004198983	A1	20041007	US 2004-829803	20040422
PRAI	US 2001-298397P	P	20010615		
	US 2002-166893	A3	20020611		
	WO 2002-EP6424	W	20020612		
OS	MARPAT 138:55873				
RE.CNT	6	THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD			

ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB Title compds. (I; A = C1-6 alkyl), were prepared Thus, succinic anhydride in CH₂Cl₂/PhNO₂ at 0-5° was treated with AlCl₃ over 30 min. then with α,α-dimethylphenylacetic acid Me ester over 20 min; after 4 h, the ice bath was removed and the reaction was allowed to proceed at room temperature for 16 h to give 80.4% of a mixture of 4-[4-(1-methoxycarbonyl-1-methylethyl)phenyl]-4-oxobutyric acid (II) and 4-[3-(1-methoxycarbonyl-1-methylethyl)phenyl]-4-oxobutyric acid. II in **tetrahydrofuran** /Et₃N at ambient temperature was treated with Et chloroformate in THF dropwise over 1 min; the mixture was allowed to stir at ambient temperature for 15 min treated with α,α-diphenyl-4-piperidinomethanol in THF over 2 min and stirred at ambient temperature for 30 min to give 85.6% 2-[4-[4-[4-(hydroxydiphenylmethyl)piperidine-1-yl]-4-oxobutyryl]phenyl]-2-methylpropionic acid Me ester. The latter was refluxed 1 h with BH₃.Me₂S in THF to give 96.6% 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-α,α-dimethylbenzeneacetic acid Me ester. This was refluxed 3 h with aqueous NaOH in MeOH to give 85% **fexofenadine**.

L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:217319 CAPLUS

DN 137:210375

TI Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of **fexofenadine**

AU Dresser, George K.; Bailey, David G.; Leake, Brenda F.; Schwarz, Ute I.; Dawson, Paul A.; Freeman, David J.; Kim, Richard B.

CS Department of Medicine, University of Western Ontario, London, ON, Can.

SO Clinical Pharmacology & Therapeutics (St. Louis, MO, United States) (2002), 71(1), 11-20

CODEN: CLPTAT; ISSN: 0009-9236

PB Mosby, Inc.

DT Journal

LA English

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB The authors' objective was to examine the effect of different fruits and their constituents on P-glycoprotein and organic anion transporting polypeptide (OATP) activities in vitro and on drug disposition in humans. Methods: P-glycoprotein-mediated digoxin or vinblastine efflux was determined in polarized epithelial cell monolayers. OATP-mediated **fexofenadine** uptake was measured in a transfected cell line. The oral pharmacokinetics of 120 mg **fexofenadine** was assessed with water, 25%-strength grapefruit juice, or normal-strength grapefruit, orange, or apple juices (1.2 L over 3 h) in a randomized 5-way crossover study in 10 healthy subjects. Results: Grapefruit juice and segments and apple juice at 5% of normal strength did not alter P-glycoprotein activity. Grapefruit extract reduced transport. 6',7'-Dihydroxybergamottin had modest inhibitory activity (50% inhibitory concentration [IC₅₀], 33 μmol/L). In contrast, grapefruit, orange, and apple juices at 5% of normal strength markedly reduced human OATP and rat oatp activity. 6',7'-Dihydroxybergamottin potently inhibited rat oatp3 and oatp1 (IC₅₀, 0.28 μmol/L). Other **furanocoumarins** and bioflavonoids also reduced rat oatp3 activity. Grapefruit, orange, and apple juices decreased the **fexofenadine** area under the plasma concentration-time curve (AUC), the peak plasma drug concentration (C_{max}), and the urinary excretion values to 30 to 40% of those with water, with no change in the time to reach C_{max}, elimination half-life, renal clearance, or urine volume in humans. Change in **fexofenadine** AUC with juice was variable among individuals and inversely dependent on value with water. Conclusions: Fruit juices and constituents are more potent inhibitors of OATPs than P-glycoprotein activities, which can reduce oral drug

bioavailability. Results support a new model of intestinal drug absorption and mechanism of food-drug interaction.

IT Flavonoids

RL: BSU (Biological study, unclassified); BIOL (Biological study) (bioflavonoids; citrus **furanocoumarins** and bioflavonoids on organic anion transporting polypeptide-mediated drug uptake of **fexofenadine**)

IT Furocoumarins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (citrus **furanocoumarins** and bioflavonoids on organic anion transporting polypeptide-mediated drug uptake of **fexofenadine**)

IT 117-39-5, Quercetin 480-41-1, Naringenin 484-20-8, 5-Methoxypsoralen 520-26-3, Hesperidin 520-33-2, Hesperitin 7380-40-7, Bergamottin 10236-47-2, Naringin 145414-76-2, 6',7'-Dihydroxybergamottin
RL: BSU (Biological study, unclassified); BIOL (Biological study) (citrus **furanocoumarins** and bioflavonoids on organic anion transporting polypeptide-mediated drug uptake of **fexofenadine**)

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:425758 CAPLUS

DN 131:63456

TI Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine

IN Jensen, Peder K.; Lorber, Richard R.; Danzig, Melvyn R.; Medeiros, Paul T.

PA Schering Corporation, USA

SO PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932125	A1	19990701	WO 1998-US26223	19981221
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 9811731	A	19990621	ZA 1998-11731	19981221
	CA 2315721	AA	19990701	CA 1998-2315721	19981221
	AU 9919071	A1	19990712	AU 1999-19071	19981221
	AU 758771	B2	20030327		
	BR 9814417	A	20001010	BR 1998-14417	19981221
	EP 1041990	A1	20001011	EP 1998-963828	19981221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO				
	JP 2001526232	T2	20011218	JP 2000-525116	19981221
	NZ 520907	A	20040528	NZ 1998-520907	19981221
	NO 2000003288	A	20000822	NO 2000-3288	20000622
PRAI	US 1997-68638P	P	19971223		
	US 1998-78638P	P	19980319		
	NZ 1998-504832	A1	19981221		
	WO 1998-US26223	W	19981221		

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB The invention relates to a pharmaceutical composition useful in the treatment of sneezing, itching runny nose, nasal congestion, redness of the eye,

tearing, itching of the ears or palate, shortness of breath, inflammation of the bronchial mucosa, reduced Forced Expiratory Volume In One Second (FEV1), coughs, rash, itchy skin, headaches, and aches and pains associated with seasonal allergic rhinitis, perennial allergic rhinitis, common colds, otitis, sinusitis, allergy, asthma, allergic asthma and/or inflammation, in a mammalian organism in need of such treatment. The composition comprises: (i) an effective amount of at least one leukotriene antagonist selected from (a) montelukast, (b) 1-(((R)- (3-(2-(6,7-difluoro-2-quinolinyl)ethenyl)phenyl)-3-(2-(2-hydroxy-2-propyl)phenyl)propyl) thio)methylcyclopropaneacetic acid; (c) 1-(((1(R)-3-(3-(2-(2,3-dichlorothieno[3, 2-b]pyridin-5-yl) -(E)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl) phenyl)propyl) thio)methyl)cyclopropaneacetic acid; (d) pranlukast; or (f) [2-[[2-(4-tert-butyl-2-thiazolyl) -5-benzofuranyl] oxymethyl]phenyl] acetic acid; or a pharmaceutically acceptable salt thereof; in admixt. with (ii) an effective amount of at least one antihistamine which is descarboethoxyloratidine, cetirizine, **fexofenadine**, ebastine, astemizole, norastemizole, epinastine, efletirizine or a pharmaceutically acceptable salt thereof.